U.S. company trials coronavirus vaccine in Australia
A U.S. biotechnology company has begun human trials in Australia of a vaccine for the coronarvirus with hopes of releasing a proven vaccine this year.
CANBERRA, Australia — A U.S. biotechnology company announced on Tuesday the start of human trials in Australia of a vaccine for the coronarvirus with hopes of releasing a proven vaccine this year.
Novavax has begun the first phase of the trial in which 131 volunteers in the cities of Melbourne and Brisbane will test the safety of the vaccine and look for early signs of the vaccine’s effectiveness, the company’s research chief Dr. Gregory Glenn said.
“We are in parallel making doses, making vaccine in anticipation that we’ll be able to show it’s working and be able to start deploying it by the end of this year,” Glenn told a virtual press conference in Melbourne from Novavax’ headquarters in Maryland.
Animal testing suggested the vaccine is effective in low doses. Novavax could manufacture at least 100 million doses this year and 1.5 billion in 2021, he said.
Manufacture of the vaccine, named NVX-CoV2373, was being scaled up with $388 million invested by Norway-based Coalition for Epidemic Preparedness Innovations since March, Glenn said.
About a dozen experimental vaccines are in early stages of testing or poised to start, mostly in China, the U.S. and Europe. It’s not clear that any of the candidates ultimately will prove safe and effective. But many work in different ways, and are made with different technologies, increasing the odds that at least one approach might succeed.
The results of the first phase of clinical trials in Australia are expected to be known in July, Novavax said. Thousands of candidates in several countries would then become involved in a second phase.
The trial began with six volunteers being injected with the potential vaccine in Melbourne on Tuesday, said Paul Griffin, infectious disease expert with Australian collaborator Nucleus Network.
Most of the vaccine shots in the pipeline aim to train the immune system to recognize the “spike” protein that studs the coronavirus’ outer surface, priming the body to react if it ever encountered the real infection. Some candidates are made using just the genetic code for that protein, and others use a harmless virus to deliver the protein-producing information. Still other vaccine candidates are more old-fashioned, made with the killed whole virus.
Novavax adds another new kind to that list, what’s called a recombinant vaccine. Novavax used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. Scientists extracted and purified the protein, and packaged it into virus-sized nanoparticles.
“The way we make a vaccine is we never touch the virus,” Novavax told The Associated Press last month. But ultimately, “it looks just like a virus to the immune system.”
It’s the same process that Novavax used to create a nanoparticle flu vaccine that recently passed late-stage testing.A U.S. biotechnology company announced on Tuesday the start of human trials in Australia of a vaccine for the coronarvirus with hopes of releasing a proven vaccine this year.